WO2003039612A1 - Intraluminal device with a coating containing a therapeutic agent - Google Patents
Intraluminal device with a coating containing a therapeutic agent Download PDFInfo
- Publication number
- WO2003039612A1 WO2003039612A1 PCT/BE2002/000166 BE0200166W WO03039612A1 WO 2003039612 A1 WO2003039612 A1 WO 2003039612A1 BE 0200166 W BE0200166 W BE 0200166W WO 03039612 A1 WO03039612 A1 WO 03039612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- fat
- therapeutic agent
- weight
- fatty acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
Definitions
- the present invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device, provided with at least one coating containing a therapeutic agent comprised in a matrix which sticks to the intraluminal device.
- Another method is the coverage of an endoluminal prosthesis with a polymer coating and the impregnation of the polymer with a therapeutic agent (EP-A-0623354, ).
- the disadvantages of this method are the limited drug capacity of the coating and the too fast release of the therapeutic agent because of the large contact area.
- polymers need a quite aggressive polymerisation step that can result in inactivation of the therapeutic agent and most polymers are not very bio-compatible and induce a foreign body inflammatory response, resulting in even more hyperplasia and restenosis.
- the object of the present invention is therefore to provide a new intraluminal device which is provided with a coating which does not need an aggressive polymerisation step, which is bio-compatible and which enables to obtain a sustained local release of the therapeutic agent.
- the intraluminal device according to the invention is characterised in that the matrix which comprises the therapeutic agent is formed by a bio-compatible oil or fat.
- an oil or fat adheres sufficiently strongly to the intraluminal device so that most of the coating remains on the intraluminal device when inserting it in the lumen.
- the oil or fat matrix further slows down the release of the therapeutic agent once inserted in the body lumen. Due to the selection of a bio- compatible oil or fat, the coating reduces the foreign body inflammatory response induced by the intraluminal device.
- a further advantage of an oil or fat coating is that it has a lubricating effect so that no further lubricants have to be used which may reduce the bio-compatibility of the intraluminal device.
- bio-compatible oil or fat is meant is the present specification that the oil or fat does not have any intolerable adverse effect on the lumen structure wherein the intraluminal device is to be applied.
- oils or fat is further used to designated substances which have the physical characteristics of an oil or a fat, a fat differing only in one respect from an oil, a fat being solid at room temperature whilst an oil is liquid at room temperature. In liquid state, i.e. at a sufficiently high temperature, oils and fats have a viscous consistency and a characteristic unctuous feel. They are moreover lighter than water and insoluble in it.
- mineral oils may be bio-compatible, animal or vegetable oils are suitable, in particular edible oils such as fish oil, olive oil, linseed oil, sunflower oil, corn oil and/or palm or palmnut oil. Good effects have been demonstrated experimentally for cod-liver oil and olive oil.
- the oils do not need to be used in their natural form but the chemical structure thereof can be modified.
- the natural, biological oils can in particular be hydrogenated (preferably only partially so that they still contain unsaturated fatty acids) resulting in an increased melting point. Further, it is possible to produce synthetic oils or fats having a composition similar to the composition of the natural oils or to the composition of particular components thereof, in particular triglycerides.
- the oils comprise triglycerides composed of glycerol and one or more fatty acids. Preferably, they comprise more than 20% by weight, and most preferably more than 70% by weight of triglycerides. These amounts are either present in the natural oils or they can be achieved by adding triglycerides or by further purifying the oils. In other embodiments of the present invention, it is however possible to substitute other trihydroxy or polyhydroxy compounds for the glycerol. A special preference is given to cod-liver oil which is purified so that it contains more than 90% of triglycerides.
- the oils or fats may also contain free fatty acids (having a free -COOH group) but this preferably in an amount of less than 50% by weight and more preferably only in minor proportions, e.g. less than about 10% by weight free fatty acids.
- the oils or fats can further be composed of, or may comprise other fatty acid derivatives, in particular methyl or ethyl esters of fatty acids.
- An example of a further "oily" or "fatty" substance which can be used as bio-compatible oil or fat is alfa-tocopherol and/or a derivative thereof such as alfa-tocopherol acetate.
- the alfa-tocopherol and/or a derivative thereof may either be a component of the oil or fat or the oil or fat may consist substantially entirely of this compound.
- tocopherol vitamin
- the oil or fat forming the matrix which sticks to the intraluminal device may thus be formed partially or completely by the therapeutic agent when this therapeutic agent is an oil or a fat.
- this therapeutic agent is an oil or a fat.
- one or more further therapeutic agents can be incorporated in the thus formed oil or fat matrix.
- alfa-tocopherol and/or derivatives thereof are preferably used in combination with an oil or fat comprising fatty acids and/or derivatives thereof, in particular one or more triglycerides. They have found more particularly that coatings containing this combination showed a very good bio-compatibility to vascular tissue. The observed effects on the decrease on the inflammation score, and especially on the decrease of the area stenosis and of the neointimal hyperplasia, indicating the occurrence of synergetic effects.
- the alfa-tocopherol and/or the derivatives thereof are preferably mixed with the oil or fat comprising fatty acids and/or derivatives thereof to achieve such synergetic effects but a top coat of the alfa-tocopherol and/or the derivatives thereof on a first oil or fat coating appeared to provide also good results.
- a top coat comprises preferably said alfa-tocopherol and/or said derivative thereof in an amount of at least 90% by weight and most preferably in an amount of at least 95% by weight.
- this oil or fat comprises the alfa-tocopherol, and/or the derivative thereof, preferably in an amount of between 20 and 80% by weight, more preferably in an amount of between 30 and 70% by weight.
- the therapeutic agent may also be chemically bonded to the oil or fat by any chemical bonding technique.
- the oil or fat comprises for example triglycerides
- the therapeutic agent may for example be chemically bound to the fatty acid groups or to the glycerol group.
- the fatty acid groups themselves may be formed by fatty acids which may be therapeutic agents.
- Such fatty acids are in particular unsaturated fatty acids, more particularly omega-3 fatty acids.
- the fatty acids are preferably formed by more than 5%, more preferably by more than 10% and most preferably by more than 15% by weight of unsaturated fatty acids.
- these unsaturated fatty acids comprise eicosapantaenoic acid (EPA) and optionally decosahexaenoic acid (DHA).
- EPA eicosapantaenoic acid
- DHA decosahexaenoic acid
- cod-liver oil and olive oil may be explained by their anti-oxidant and anti-inflammatory effect, in particular the anti-oxidant effect of their unsaturated fatty acids.
- This anti- oxidant effect can be increased by added or naturally present vitamin E or derivatives thereof having an anti-oxidant effect (for example when the oil or fat has been hydrogenated partially).
- bio-compatible oils inhibit smooth muscle cell proliferation in cell culture experiments.
- the therapeutic agent may also be mixed with the oil or fat.
- the therapeutic agent When soluble in the oil or fat, the therapeutic agent can be dissolved therein or, when it is not soluble in the oil or fat, it can be dispersed therein, more particularly emulsified or suspended depending on the fact whether the therapeutic agent is a liquid or a solid.
- the therapeutic agent may be selected from the group consisting of vinblastine, sirolimus, mitoxantrone, tacrolimus, paclitaxel, cytochalasin, latrunculin, and everolimus, a particular preference being given to everolimus.
- It can also be selected from the group consisting of deferoxamine, geldanamycin, nigericin, penitrem, paxilline, verruculogen, KT5720, KT5823, Anisomycin, chelerythrine chloride, genistein, parthenolide, trichostatin A, T2 toxin, Zearalenone, Interferon, epithalon- D, Ca-ionophore, 4 bromo Ca lonophore, Aflatoxins, aphidicolin, brefeldin A, cerulenin, chromomycin A3, citrinin, cyclopiazonic acid, forsokolin, fumagillin, fumonisins B1 , B2, hypericin, K252, mycophenolic acid, ochratoxin A, and oligomycin or further from the group consisting of mycophenolic acid, mycophenolate mofetil, mizo bine, methylprednisolone, dexamethas
- the therapeutic agent may have different effects and may in this respect be selected amongst immunosuppressants, anti- inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, calcium channel blockers, anti-neoplasties, antibodies, anti-thrombotics, anti-platelet agents, llb/llla blockers, antiviral agents, anti-cancer agents, chemotherapeutics, thrombolytics, vasodilators, antibiotics, growth factor antagonists, free radical scavengers, radiopaque agents, anti-angiogenesis agents, angiogenesis drugs, cyclooxygenase inhibitors, phosphodiesterase inhibitors, cytokine inhibitors, nitrogen oxide donors, and cytokine activators.
- the coating provided on the intraluminal device in accordance with the present invention may comprise other substances in addition to the therapeutic agent and the oil or fat. It is for example possible to add some substances, in particular some natural or synthetic polymeric substances, binders, thickening agents, etc. to the coating in order to stabilise it.
- the amount of such substances is however preferably kept below 30%, more preferably below 85% and most preferably below 95% by weight in order to maintain the improved bio- compatibility of the oil or fat coating as much as possible.
- the coating comprises preferably at least 70% by weight, more preferably at least 85% by weight and most preferably at least 95% by weight of the oil or fat and the therapeutic agent.
- the oil or fat content of the coating is preferably at least 50% by weight, more preferably at least
- a top coat can be applied on top of this coating, in particular a top coat of the same or a different bio-compatible oil or fat.
- the rate at which the therapeutic agent is delivered can further be controlled by the ratio of therapeutic agent to oil or fat in the coating or by providing multiple coatings with varying drug concentrations.
- the release of therapeutic agent can further be controlled by the selection of an appropriate bio- compatible oil or fat having a certain stability level and melting point.
- the oil or fat has preferably a melting point lower than 100°C and more preferably lower than 80°C so that the therapeutic agent can be mixed with the oil or fat in the molten state thereof without having a deleterious effect on the therapeutic agent.
- the melting temperature is preferably even lower than 60°C, more preferably lower than 40°C, so that a mixture can be made of the therapeutic agent, the oil or fat in its molten state and a volatile solvent such a ethanol.
- the melting point of the oil or fat is preferably lower or equal to 37°C so that the oil or fat will be in the molten state once inserted in the body lumen.
- the oil or fat may be an oil at room temperature.
- the above mentioned natural oils are for example liquid at room temperature, except palm oil and palm nut oil.
- Linseed oil, sunflower oil, corn oil, olive oil and cod-liver oil have a melting point lower or equal to about 0°C.
- these oils are able to stick sufficiently strongly to the intraluminal device.
- these unsaturated oils can be further stabilised by a partial hydrogenation resulting in an increase of their melting point.
- the melting point can be raised to a melting point higher than 10, 15, 20 or 30°C depending on the desired stability (viscosity) of the oil or fat and the release properties thereof.
- the hardened oil or fat When use is made of a chemically hardened oil or fat which still comprises unsaturated fatty acid chains, the hardened oil or fat is preferably free of trans isomers of unsaturated fatty acid chains. Natural oils are normally free of such trans isomers. During the usual hardening processes, trans isomers are however formed. Since such trans isomers may have negative effects, they are preferably removed, for example in accordance with the technique described in WO 98/54275.
- the present invention also relates to a method for providing an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device, with at least one coating containing a therapeutic agent comprised in a matrix which sticks to the intraluminal device.
- the matrix is formed by a bio- compatible oil or fat, which comprises said therapeutic agent, and which is applied in a flowable state onto the device.
- the oil or fat When the oil or fat has a sufficiently low viscosity (optionally after heating), it can be applied in a molten state onto the device.
- a solvent which is mixed with the oil or fat before applying the oil or fat onto the device and, after having applied the mixture of solvent and oil or fat onto the device, the solvent is allowed to evaporate.
- the solvent is normally an organic solvent, in particular an alcohol such as ethanol.
- a solution of the oil or fat in the solvent can first be made after which the therapeutic agent, when not yet comprised in the oil or fat, can be added.
- the therapeutic agent when not yet comprised in the oil or fat, can be added.
- a homogeneous mixture is first made, in particular an emulsion.
- the therapeutic agent can first be dissolved or dispersed in the solvent before mixing it with the oil or fat.
- a typical method according to a preferred embodiment of the present invention comprises the following steps: a) Cleaning, degreasing and drying of the prosthesis b) Dipping of the prosthesis in an deoxidative solution and airdrying it c) Making an emulsion or solution of the bio-compatible oil or fat and a solvent, preferably in a liquid state of the oil or fat d) In this emulsion/solution a therapeutic agent is dissolved when the oil or fat did not yet contain a therapeutic agent or an additional therapeutic agent is dissolved when the oil or fat did already contain a therapeutic agent.
- the therapeutic substance needs only to be dispersed throughout the solvent/oil emulsion or solution so that it may be either in a true solution with the solvent/oil emulsion or solution or dispersed in fine particles in the solvent/oil emulsion or solution.
- g) Airdry till the solvent is evaporated.
- a therapeutic agent could already be added to the solvent or to the oil or fat.
- the oil or fat could for example be enriched with EPA and optionally DHA. It is also possible to add alfa- tocopherol and/or a derivative thereof to the oil or fat.
- an oil or fat can be selected which comprises already groups which are therapeutically active, such as unsaturated fatty acid groups, or a therapeutic agent can be bonded to the oil or fat using any chemical bonding technique.
- the oil or fat is already provided in this way with a therapeutic agent, it is not necessary any more to add a therapeutic agent although it is still possible to add further therapeutic agents. This is for example the case when the oil is formed by alfa- tocopherol or a derivative thereof or when the oil comprises alfa- tocopherol or a derivative thereof.
- topcoat consisting of a bio-compatible oil or fat, in particular a natureal edible oil or alfa-tocopherol (or an derivative thereof) or a combination thereof can be using dipcoating, spraycoating or any other coating method .
- the obtained coated prosthesis can be used as such or further dried and sterilised. Light-protection of the obtained coated prosthesis is advisable to maintain the bio-compatible characteristics when stored.
- a bio-compatible, in particular a biological oil or fat in intimate contact with a drug covering the prosthesis allows the drug to be retained in the prosthesis in a resilient matrix during expansion of the prosthesis and also slows the administration of drug following implantation.
- the oil can become a fat, retaining the drug and resulting in a more stable surface coating.
- certain chemical substances (bicarbonate) or by hydrogenation the coating can be further stabilised resulting in a very stable drug containing coating.
- the method of the invention can be used whether the prosthesis has a metallic or polymeric surface.
- the method is also an extremely simple one since it can be effected by simply immersing the prosthesis into the solution (emulsion) or by spraying the solution (emulsion) onto the prosthesis.
- the amount of drug to be included onto the prosthesis can be readily controlled by using different drug concentrations and or different coating application methods.
- the rate at which the drug is delivered can be controlled by the selection of an appropriate bio- compatible oil or fat at a certain stability level and melting point and by the ratio of drug to oil in the solution.
- the release rate can be further controlled by using additional barrier coatings or multiple layers of coating with varying drug concentrations. Furthermore this system allows the use of different therapeutic agents.
- prosthesis made according to the present invention can deliver drugs to a body lumen by introducing the prosthesis transluminally into a selected portion of the body lumen and radially expanding the prosthesis into contact with the body lumen.
- the transluminal delivery can be accomplished by a catheter designed for the delivery of the prostheses and the radial expansion can be accomplished by balloon expansion of the prosthesis, by self-expansion of the prosthesis or a combination of self-expansion and balloon expansion.
- the present invention provides a prosthesis which may be delivered and expanded in a selected body lumen or conduit without losing a therapeutically significant amount of a drug or gene applied thereto. It also provides a drug or gene containing prosthesis which allows for a sustained release of the drug or gene to luminal or conduit tissue.
- the underlying structure of the prosthesis used according to the invention can be virtually any prosthesis design, for example of the self-expanding type or of the balloon expandable type, and of metal or polymeric material.
- metal prosthesis designs such as those disclosed in US-A-4.733.665 (Palmaz) and US-A-5.603.721 (Lau) could be used in the present invention.
- prosthesis with special surface treatments or special designs to optimise local drug delivery are especially suitable for this invention (for example: DE199 16 086 A1 , EP O 950 386 A2, EP 1 132 058 A1 , WO 01/66036 A2, WO 98/23228, US 5.902.266, US 5.843.172, ).
- the surface of the prosthesis could in particular be provided with perforating holes or pits which can be filled with the coating material to increase the load of therapeutic agent and/or to slow down the release. After having applied the coating, the surface of the prosthesis next to the holes or pits can be wiped off or cleaned to remove the coating material.
- the present invention therefore does not only embrace continuous coatings covering the entire prosthesis but also discontinuous local coatings or combinations of local coatings and continuous top coatings applied thereover.
- the coating further does not need to be applied on the surface of the prosthesis.
- the coating may be located within the pores of the prosthesis.
- the prosthesis could be made of virtually any bio- compatible material having physical properties suitable for the design.
- tantalum, nitinol and stainless steel have been proven suitable for many such designs and could be used in the present invention.
- prostheses made of biostable or bioabsorbable polymers such as poly(ethylene terephthalate), polyacetal, poly(lactic acid), polyethylene oxide)/poly(butylene terephthalate) copolymer could be used in the present invention.
- the prosthesis surface should be clean and free from contaminants that may be introduced during manufacturing, the prosthesis surface requires no particular surface treatment in order to retain the coating applied in the present invention.
- the oil or fat chosen should be bio-compatible and minimise irritation to the vessel wall when the prosthesis is implanted.
- the ratio of therapeutic substance to the oil/solvent emulsion in the solution will depend on the efficacy of the oil or fat in securing the therapeutic substance onto the prosthesis and the rate at which the coating is to release the therapeutic substance to the tissue of the blood vessel or body conduit. More oil or fat may be needed if it has relatively poor efficacy in retaining the therapeutic substance on the prosthesis and more oil may be needed in order to provide an elution matrix that limits the elution of a very soluble therapeutic substance.
- a wide ratio of therapeutic substance to oil/solvent emulsion could therefore be appropriate, in particular a weight ratio ranging from about 100:1 to 1 :100.
- Balloon mounted stainless steel balloon-expandable coronary stents 16mm long, were used for these studies.
- the bare stents were sterile and dipped in a bicarbonate solution and air-dried, then dipcoated in the oil coating solution.
- the coated stents were air-dried or sterilized with ethylene oxide before implantation in porcine coronary arteries.
- the surface characteristics of the coated stents were examined by light and scanning electron microscopy (SEM).
- control bare stents and oil coated stents (cod-liver oil (CLO), alfa-tocopherol oil solution (VIT E), CLO+VIT E, in each group 5 stents) were randomly implanted in the coronary arteries of pigs. Pigs were sacrificed after 5 days to evaluate acute inflammatory response and thrombus formation.
- CLO cod-liver oil
- VIT E alfa-tocopherol oil solution
- CLO+VIT E CLO+VIT E
- the guiding catheter was used as a reference to obtain an oversizing from 10 to 20%.
- Tissue processing for histomorphometric analysis At 5 days or 4 weeks follow-up, the pigs were sacrificed and the stented coronary arteries were perfused with a 10% formalin solution at ⁇ OmmHg. Artery segments were carefully dissected together with minimum a 1 cm vessel segment both proximal and distal to the stent. The segments were furthermore fixed in a 10% formalin solution. Each segment was cut into a proximal, middle and distal stent segment for histomorphometric analysis. Tissue specimens were embedded in a cold- polymerizing resin (Technovit 7100, Heraus Kulzer GmbH, and Wehrheim, Germany).
- the mean score was calculated as the sum of scores for each filament/ number of filament present.
- Morphometric analysis of the coronary segments harvested was performed on 3 slices (proximal, middle and distal stent part) by using a computerized morphometry program (Leitz CBA 8000). The areas of respectively the arterial lumen, the area inside the internal elastic lamina (IEL), and the area inside the external elastic lamina (EEL) were measured. Furthermore, the area stenosis (1-Iumen area/IEL area) and the area of neointimal hyperplasia (IEL area - lumen area) were calculated. Statistics For comparison among different groups, the non-paired t-test is used. Data are presented as mean value ⁇ SD. A p value ⁇ 0.05 was considered as statistically significant. Results SEM images of the coated stents The thickness of coating covering the stent filaments was 10 ⁇ m. The stent surface was smooth . Histopathologic findings (Table 1 )
- the bare and all CLO coated stents induced an identical histopathological response.
- the stent filaments showed a good alignment to the vascular wall. Internal elastic membrane was beneath the stent filaments and the media was compressed. Arterial injury induced by stent implantation was not significant different among the groups. A thin fibrin layer covering the stent filaments was observed. A few inflammatory cells trapped within a thrombotic meshwork covering the stent struts were observed. No significant different inflammatory score and thrombus score of CLO coated stents and bare stents were observed.
- the lumen area of bare stents was significantly larger than the VIT E coated stents (5.17 ⁇ 1.19 vs 4.19 ⁇ 0.93, P ⁇ 0.001 ), but smaller than CLO+ VIT E coated stents (5.17 ⁇ 1.19 vs 6.37 ⁇ 0.97, P ⁇ 0.01 ).
- the neointimal hyperplasia of bare stents was comparable to VIT E stents, but higher than CLO coated stents (1.50 ⁇ 0.76 vs 1.25 ⁇ 0.61 , P>0.05) and CLO+VIT E coated stents(1.50 ⁇ 0.76 vs 0.96 ⁇ 0.20, P ⁇ 0.05).
- Table 1 Histomorphometric response to the coated stents at 4 weeks follow-up
- VIT E coated stents may be caused by smaller selected stented arteries as the neointimal hyperplasia of VIT E coated stents was comparable to bare stents.
- all CLO, VIT E and CLO+VIT E coatings showed an excellent bio-compatibility to vascular tissue and could therefore serve as a vehicle for local drug delivery. The best results were obtained with the CLO+VIT E combination.
- Tacrolimus (1 mg) was dissolved in an emulsion of 50% highly purified eicosapentaenoic (EPA) enriched oil and 50% pure ethanol. After intense stirring during 5 min a homogeneous solution was obtained. Stents were cleaned and degreased and dried. They were dipped in a Sodium bicarbonate solution during 30 seconds, air-dried and than dipped in the Tacrolimus/eicosapentaenoic(EPA) enriched oil/ethanol emulsion. The stents were air-dried in a warm laminar flow to let evaporate the ethanol and a thin, homogeneous coating layer was obtained. Stents were repeatedly (3X) dipped and dried . Thereafter the stents were immerced in an alfa-tocopherol/ethanol solution and again airdried. Total Tacrolimus amount obtained on one stent was 800 ⁇ g.
- EPA eicosapentaenoic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002466432A CA2466432A1 (en) | 2001-11-08 | 2002-11-08 | Intraluminal device with a coating containing a therapeutic agent |
JP2003541902A JP2005507754A (en) | 2001-11-08 | 2002-11-08 | Intraluminal device having a coating containing a therapeutic agent |
EP02776619A EP1463545B3 (en) | 2001-11-08 | 2002-11-08 | Intraluminal device with a coating containing a therapeutic agent |
US10/494,892 US8460693B2 (en) | 2001-11-08 | 2002-11-08 | Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent |
DE60221287T DE60221287T4 (en) | 2001-11-08 | 2002-11-08 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT |
DE60221287A DE60221287D1 (en) | 2001-11-08 | 2002-11-08 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT |
US11/140,811 US20060008501A1 (en) | 2001-11-08 | 2005-05-31 | Intraluminal device with a coating containing a therapeutic agent |
US12/767,289 US20100209473A1 (en) | 2001-11-08 | 2010-04-26 | Intraluminal device with a coating containing a therapeutic agent |
US13/912,913 US20130274319A1 (en) | 2001-11-08 | 2013-06-07 | Intraluminal device with a coating containing a therapeutic agent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01870237 | 2001-11-08 | ||
EP01870237.3 | 2001-11-08 | ||
EP02447048 | 2002-03-28 | ||
EP02447048.6 | 2002-03-28 | ||
EP02447075.9 | 2002-04-26 | ||
EP02447075 | 2002-04-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/140,811 Division US20060008501A1 (en) | 2001-11-08 | 2005-05-31 | Intraluminal device with a coating containing a therapeutic agent |
US13/912,913 Division US20130274319A1 (en) | 2001-11-08 | 2013-06-07 | Intraluminal device with a coating containing a therapeutic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003039612A1 true WO2003039612A1 (en) | 2003-05-15 |
Family
ID=27224430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000166 WO2003039612A1 (en) | 2001-11-08 | 2002-11-08 | Intraluminal device with a coating containing a therapeutic agent |
Country Status (9)
Country | Link |
---|---|
US (4) | US8460693B2 (en) |
EP (4) | EP1842567A3 (en) |
JP (2) | JP2005507754A (en) |
AT (2) | ATE367172T1 (en) |
CA (2) | CA2508907A1 (en) |
DE (3) | DE60235775D1 (en) |
DK (1) | DK1576970T3 (en) |
ES (1) | ES2289153T7 (en) |
WO (1) | WO2003039612A1 (en) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016399A1 (en) * | 2003-08-11 | 2005-02-24 | Scimed Life Systems, Inc. | Medical devices containing antioxidant and therapeutic agent |
WO2005053767A1 (en) * | 2003-11-11 | 2005-06-16 | K.U. Leuven Research & Development | Cis-hydrogenated fatty acid coating of medical devices |
JP2005199058A (en) * | 2003-12-19 | 2005-07-28 | Cordis Corp | Local vascular delivery of trichostatin alone or by its combination with sirolimus for preventing restenosis after vascular defect |
WO2005082434A3 (en) * | 2004-02-28 | 2005-10-13 | Hemoteq Gmbh | Biocompatible coating, method, and use of medical surfaces |
US20060067975A1 (en) * | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | UV cured gel and method of making |
EP1663343A2 (en) * | 2003-09-15 | 2006-06-07 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
EP1683531A1 (en) * | 2005-01-19 | 2006-07-26 | Heraeus Kulzer GmbH | Antibiotic coating of implants |
JP2007500041A (en) * | 2003-07-30 | 2007-01-11 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Bioabsorbable coating for implantable devices and method of making the same |
JP2007509179A (en) * | 2003-10-21 | 2007-04-12 | メドロジックス・ディバイス・コーポレーション | Treatment of gamma-tocopherol for the prevention of restenosis |
EP1880690A1 (en) * | 2006-07-17 | 2008-01-23 | Heraeus Kulzer GmbH | Dental implant system part with coating |
EP1886701A2 (en) * | 2006-08-07 | 2008-02-13 | BIOTRONIK VI Patent AG | Marker composite for medical implants |
DE102007036685A1 (en) | 2007-08-03 | 2009-02-05 | Innora Gmbh | Improved drug-coated medical devices their manufacture and use |
EP2077127A2 (en) * | 2001-10-22 | 2009-07-08 | EV3 Peripheral, Inc. | Stent coatings containing HMG-CoA reductase inhibitors |
US20090181937A1 (en) * | 2004-09-28 | 2009-07-16 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20090208552A1 (en) * | 2004-09-28 | 2009-08-20 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP2111880A2 (en) | 2008-04-24 | 2009-10-28 | BIOTRONIK VI Patent AG | Biodegradable metal stent |
US20100004738A1 (en) * | 2005-04-29 | 2010-01-07 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
EP2191853A1 (en) * | 2007-09-28 | 2010-06-02 | Terumo Kabushiki Kaisha | In-vivo indwelling matter |
US7947015B2 (en) | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8100855B2 (en) | 2007-09-17 | 2012-01-24 | Abbott Cardiovascular Systems, Inc. | Methods and devices for eluting agents to a vessel |
US8124127B2 (en) * | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US8263102B2 (en) * | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
WO2013007653A1 (en) | 2011-07-08 | 2013-01-17 | Cardionovum Sp.Z.O.O. | Balloon catheter with a sirolimus coated catheter balloon for controlled release of sirolimus |
US8388573B1 (en) | 2006-06-28 | 2013-03-05 | Abbott Cardiovascular Systems Inc. | Local delivery with a balloon covered by a cage |
US8512734B2 (en) * | 2004-07-05 | 2013-08-20 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Biocompatible coating of medical devices |
US8574627B2 (en) * | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US8871883B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible coating for implantable medical devices |
US8871236B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8916188B2 (en) | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US8961588B2 (en) | 2002-03-27 | 2015-02-24 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US9050442B2 (en) | 1999-01-25 | 2015-06-09 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
US9101697B2 (en) | 2004-04-30 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Hyaluronic acid based copolymers |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9339592B2 (en) | 2004-12-22 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US10532189B2 (en) | 2007-08-29 | 2020-01-14 | Invatec Technology Center Gmbh | Controlled expansion balloon catheter |
US10864304B2 (en) | 2009-08-11 | 2020-12-15 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60235775D1 (en) | 2001-11-08 | 2010-05-06 | Ziscoat N V | Intraluminal device with a therapeutic agent-containing coating |
US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
US20030171734A1 (en) * | 2002-01-22 | 2003-09-11 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
US8021331B2 (en) * | 2003-09-15 | 2011-09-20 | Atrium Medical Corporation | Method of coating a folded medical device |
US20060083768A1 (en) * | 2004-09-28 | 2006-04-20 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
CA2527666C (en) * | 2004-12-16 | 2008-09-23 | Miv Therapeutics Inc. | Multi-layer drug delivery device and method of manufacturing same |
EP2031974A1 (en) * | 2006-05-17 | 2009-03-11 | Ziscoat N.V. | Fatty acid triglycerides for making biocompatible coatings |
CN102258811B (en) * | 2006-07-03 | 2015-03-11 | 汉莫堤克股份有限公司 | Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open |
JP5100084B2 (en) * | 2006-10-26 | 2012-12-19 | 株式会社東芝 | Ultrasonic diagnostic apparatus, image processing apparatus, and image processing program |
JP2008119199A (en) * | 2006-11-10 | 2008-05-29 | Kagoshima Univ | Stent coated with medicine for suppressing production enhancement of calcineurin |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
WO2008063576A2 (en) * | 2006-11-20 | 2008-05-29 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
BRPI0806727B8 (en) | 2007-01-21 | 2021-06-22 | Hemoteq Ag | method for coating a balloon catheter |
WO2008097511A2 (en) | 2007-02-07 | 2008-08-14 | Cook Incorporated | Medical device coatings for releasing a therapeutic agent at multiple rates |
US7938286B2 (en) * | 2007-02-13 | 2011-05-10 | Gateway Plastics, Inc. | Container system |
US20080207756A1 (en) * | 2007-02-27 | 2008-08-28 | Atrium Medical Corporation | Bio-absorbable oil suspension |
WO2009048645A2 (en) * | 2007-10-10 | 2009-04-16 | Miv Therapeutics, Inc. | Lipid coatings for implantable medical devices |
US8049061B2 (en) | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
US8076529B2 (en) | 2008-09-26 | 2011-12-13 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix for intraluminal drug delivery |
US8226603B2 (en) | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
US8728150B2 (en) * | 2009-01-21 | 2014-05-20 | Meril Life Sciences Private Limited | Medical device loaded with formulation for targeted delivery of biologically active material/s and method of manufacture thereof |
ES2550634T3 (en) | 2009-07-10 | 2015-11-11 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
WO2011119536A1 (en) | 2010-03-22 | 2011-09-29 | Abbott Cardiovascular Systems Inc. | Stent delivery system having a fibrous matrix covering with improved stent retention |
CA2803361C (en) * | 2010-06-30 | 2020-07-21 | Surmodics, Inc. | Lipid coating for medical devices delivering bioactive agent |
US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
WO2013091722A1 (en) | 2011-12-23 | 2013-06-27 | Innora Gmbh | Drug-coated medical devices |
US20150231306A1 (en) * | 2014-02-19 | 2015-08-20 | Lenn R. Hann | Coated medical device |
US10390831B2 (en) * | 2015-11-10 | 2019-08-27 | Covidien Lp | Endoscopic reposable surgical clip applier |
AU2017331242B2 (en) | 2016-09-22 | 2022-07-07 | Mercator Medsystems, Inc. | Treatment of Restenosis using Temsirolimus |
KR20200008166A (en) | 2017-05-26 | 2020-01-23 | 머케이터 메드시스템즈, 인크. | Combination therapy for the treatment of restenosis |
CN111760174B (en) | 2018-03-14 | 2023-08-25 | 墨卡托医疗系统公司 | Medical device and medical method for local drug delivery |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952419A (en) * | 1987-08-31 | 1990-08-28 | Eli Lilly And Company | Method of making antimicrobial coated implants |
WO2000062830A2 (en) * | 1999-04-19 | 2000-10-26 | Boston Scientific Limited | Coating medical devices using air suspension |
WO2002100455A2 (en) * | 2001-06-08 | 2002-12-19 | Baylor College Of Medicine | Use of ozone for the prevention of infection caused by medical devices |
EP1273314A1 (en) * | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4950124A (en) * | 1972-09-27 | 1974-05-15 | ||
DE2828623C2 (en) * | 1978-06-29 | 1983-11-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | C 1 6 -to C 1 8 fatty acids, a process for their preparation and their use, labeled with radioactive fluorine |
SE8206744D0 (en) * | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | PREPARATION FOR CONTROLLED RELEASE OF SUBSTANCES |
DE3339236A1 (en) | 1983-10-28 | 1985-05-09 | Bayer Ag | PREPARATION OF MEDICINAL PRODUCTS |
SU1297865A1 (en) * | 1984-05-04 | 1987-03-23 | Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова | Method of treatment of patients ill with chronic non-specific ulcerative colitis |
HU193951B (en) * | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
JPS61291520A (en) * | 1985-06-19 | 1986-12-22 | Daigo Eiyou Kagaku Kk | Fat emulsion of erythromycin |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4847301A (en) * | 1985-11-13 | 1989-07-11 | Pennwalt Corporation | Methods of use of α-(aminoalkyl)-arylacetic acid derivatives |
US5118493A (en) * | 1986-05-02 | 1992-06-02 | Brigham And Women's Hospital | Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US6387379B1 (en) * | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US4894231A (en) * | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
DE3734147C2 (en) * | 1987-10-09 | 1998-10-29 | Braun Melsungen Ag | Isotonic omega-3 fatty acid-containing fat emulsion and its use |
US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
US5843089A (en) * | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
CA2079417C (en) | 1991-10-28 | 2003-01-07 | Lilip Lau | Expandable stents and method of making same |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
US6491938B2 (en) * | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
FR2710161B1 (en) * | 1993-09-13 | 1995-11-24 | Suisse Electronique Microtech | Miniature array of light shutters. |
CA2180260A1 (en) * | 1993-12-29 | 1995-07-06 | Dennis M. Brown | Methods and compositions for the treatment of a host with a cellular proliferative disease |
US6228383B1 (en) * | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
DE69510190T2 (en) * | 1994-03-30 | 2000-01-27 | Gs Dev Ab | USE OF FATTY ACID ESTERS AS BIO ADHESIVES |
US5716614A (en) | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5591230A (en) * | 1994-09-07 | 1997-01-07 | Global Therapeutics, Inc. | Radially expandable stent |
SE518619C2 (en) | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Controlled release composition containing monocaproin |
US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
DE4432708A1 (en) * | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modified bile acids, process for their preparation and their use |
US5509899A (en) * | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
US6262109B1 (en) * | 1995-12-22 | 2001-07-17 | Henkel Corporation | Methods of preventing and/or treating high serum levels of cholesterol and/or lipids |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
SE504582C2 (en) | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyclosporin composition based on an L2 phase |
RU2125887C1 (en) * | 1995-08-25 | 1999-02-10 | Владивостокский государственный медицинский университет | Method of liposomal interferon preparing |
US5714360A (en) * | 1995-11-03 | 1998-02-03 | Bsi Corporation | Photoactivatable water soluble cross-linking agents containing an onium group |
US6764509B2 (en) * | 1996-09-06 | 2004-07-20 | Carbomedics Inc. | Prosthetic heart valve with surface modification |
TR199900786T2 (en) * | 1996-10-11 | 1999-07-21 | Scotia Holdings Plc | Pharmaceutical compositions containing Eykoza penta enoic acid and/or stearidonic acid. |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6229032B1 (en) * | 1997-05-29 | 2001-05-08 | K. U. Leuven Research & Development | Elimination of trans-unsaturated fatty acid compounds by selective adsorption with zeolites |
DK1009387T3 (en) * | 1997-07-02 | 2006-08-14 | Euro Celtique Sa | Long-release stabilized tramadol formulations |
US5897911A (en) * | 1997-08-11 | 1999-04-27 | Advanced Cardiovascular Systems, Inc. | Polymer-coated stent structure |
US6083950A (en) * | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
EP1039893B1 (en) * | 1997-12-10 | 2011-02-02 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US6033436A (en) * | 1998-02-17 | 2000-03-07 | Md3, Inc. | Expandable stent |
US6465525B1 (en) * | 1998-03-18 | 2002-10-15 | Surmodics, Inc. | Latent reactive blood compatible agents |
DE19916086B4 (en) | 1998-04-11 | 2004-11-11 | Inflow Dynamics Inc. | Implantable prosthesis, especially vascular prosthesis (stent) |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US6197357B1 (en) * | 1998-05-28 | 2001-03-06 | University Of Massachusetts | Refined vegetable oils and extracts thereof |
DE69913342T2 (en) * | 1998-06-03 | 2004-10-28 | Blue Medical Devices B.V. | STENTS WITH DIAMOND-LIKE COATING |
US6254634B1 (en) * | 1998-06-10 | 2001-07-03 | Surmodics, Inc. | Coating compositions |
US6369039B1 (en) * | 1998-06-30 | 2002-04-09 | Scimed Life Sytems, Inc. | High efficiency local drug delivery |
EP1105169A1 (en) * | 1998-08-20 | 2001-06-13 | Cook Incorporated | Coated implantable medical device |
US6211315B1 (en) * | 1998-11-12 | 2001-04-03 | Iowa State University Research Foundation, Inc. | Lewis acid-catalyzed polymerization of biological oils and resulting polymeric materials |
KR100783299B1 (en) | 1998-12-31 | 2007-12-10 | 안지오테크 파마슈티칼즈, 인코포레이티드 | Stent grafts with bioactive coatings |
DE19900054A1 (en) * | 1999-01-04 | 2000-07-06 | Hans Dietl | Taxane-containing stable and sterile emulsion and process for their preparation |
WO2000051662A1 (en) * | 1999-03-04 | 2000-09-08 | Tepha, Inc. | Bioabsorbable, biocompatible polymers for tissue engineering |
CN1167462C (en) * | 1999-03-09 | 2004-09-22 | 杭州华东医药集团生物工程研究所有限公司 | Medicinal composition containing cyclosporin |
US6607598B2 (en) * | 1999-04-19 | 2003-08-19 | Scimed Life Systems, Inc. | Device for protecting medical devices during a coating process |
US6730349B2 (en) * | 1999-04-19 | 2004-05-04 | Scimed Life Systems, Inc. | Mechanical and acoustical suspension coating of medical implants |
US6610035B2 (en) * | 1999-05-21 | 2003-08-26 | Scimed Life Systems, Inc. | Hydrophilic lubricity coating for medical devices comprising a hybrid top coat |
JP4421699B2 (en) * | 1999-06-30 | 2010-02-24 | 大洋薬品工業株式会社 | Intravenous prostaglandin fat emulsion |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
EP1259230A2 (en) * | 2000-02-18 | 2002-11-27 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
EP1132058A1 (en) * | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US7875283B2 (en) * | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US7419678B2 (en) | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
US6451373B1 (en) * | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
EP1330273B1 (en) * | 2000-10-31 | 2007-07-25 | Cook Incorporated | Coated implantable medical device |
US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US20020120333A1 (en) * | 2001-01-31 | 2002-08-29 | Keogh James R. | Method for coating medical device surfaces |
US7056339B2 (en) * | 2001-04-20 | 2006-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery platform |
US20020159456A1 (en) * | 2001-04-27 | 2002-10-31 | Foster Michael S. | Method and system for multicasting in a routing device |
US7030127B2 (en) | 2001-06-29 | 2006-04-18 | Ethicon, Inc. | Composition and medical devices utilizing bioabsorbable polymeric waxes |
US7034037B2 (en) * | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
US6444318B1 (en) * | 2001-07-17 | 2002-09-03 | Surmodics, Inc. | Self assembling monolayer compositions |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20030077310A1 (en) * | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
DE60235775D1 (en) * | 2001-11-08 | 2010-05-06 | Ziscoat N V | Intraluminal device with a therapeutic agent-containing coating |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US20030204168A1 (en) * | 2002-04-30 | 2003-10-30 | Gjalt Bosma | Coated vascular devices |
US6645547B1 (en) | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US7048962B2 (en) * | 2002-05-02 | 2006-05-23 | Labcoat, Ltd. | Stent coating device |
EP1505931A1 (en) * | 2002-05-20 | 2005-02-16 | Orbus Medical Technologies, Inc. | Drug eluting implantable medical device |
AU2003251787A1 (en) | 2002-07-02 | 2004-01-23 | Polycord, Inc. | Polymerized and modified rapamycins and their use in coating medical prostheses |
US6767405B2 (en) | 2002-07-10 | 2004-07-27 | Carmeda Ab | Apparatus and process for coating articles |
WO2004006976A1 (en) | 2002-07-12 | 2004-01-22 | Cook Incorporated | Coated medical device |
US7732535B2 (en) * | 2002-09-05 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Coating for controlled release of drugs from implantable medical devices |
US6899729B1 (en) * | 2002-12-18 | 2005-05-31 | Advanced Cardiovascular Systems, Inc. | Stent for treating vulnerable plaque |
US20040224003A1 (en) | 2003-02-07 | 2004-11-11 | Schultz Robert K. | Drug formulations for coating medical devices |
US20040167572A1 (en) * | 2003-02-20 | 2004-08-26 | Roth Noah M. | Coated medical devices |
EP1603485A4 (en) * | 2003-02-26 | 2011-03-30 | Medivas Llc | Bioactive stents and methods for use thereof |
US20040230176A1 (en) | 2003-04-23 | 2004-11-18 | Medtronic Vascular, Inc. | System for treating a vascular condition that inhibits restenosis at stent ends |
US8021418B2 (en) | 2003-06-19 | 2011-09-20 | Boston Scientific Scimed, Inc. | Sandwiched radiopaque marker on covered stent |
CA2536961A1 (en) | 2003-08-14 | 2005-02-24 | Blue Medical Devices B.V. | Endoluminal prosthesis comprising a therapeutic agent |
GB0326180D0 (en) | 2003-11-11 | 2003-12-17 | Leuven K U Res & Dev | Biocompatible coating of medical devices |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US7303758B2 (en) | 2004-01-20 | 2007-12-04 | Cordis Corporation | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury |
US20050159809A1 (en) * | 2004-01-21 | 2005-07-21 | Medtronic Vascular, Inc. | Implantable medical devices for treating or preventing restenosis |
US7806924B2 (en) * | 2004-02-18 | 2010-10-05 | Cordis Corporation | Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis |
US8139270B2 (en) | 2007-05-31 | 2012-03-20 | Xerox Corporation | Variable data periodic line patterns for composing a font system |
-
2002
- 2002-11-08 DE DE60235775T patent/DE60235775D1/en not_active Expired - Lifetime
- 2002-11-08 DE DE60221287A patent/DE60221287D1/en not_active Expired - Lifetime
- 2002-11-08 US US10/494,892 patent/US8460693B2/en active Active
- 2002-11-08 CA CA002508907A patent/CA2508907A1/en not_active Abandoned
- 2002-11-08 EP EP07112611A patent/EP1842567A3/en not_active Ceased
- 2002-11-08 AT AT02776619T patent/ATE367172T1/en not_active IP Right Cessation
- 2002-11-08 EP EP02776619A patent/EP1463545B3/en not_active Expired - Lifetime
- 2002-11-08 JP JP2003541902A patent/JP2005507754A/en active Pending
- 2002-11-08 ES ES02776619T patent/ES2289153T7/en active Active
- 2002-11-08 CA CA002466432A patent/CA2466432A1/en not_active Abandoned
- 2002-11-08 WO PCT/BE2002/000166 patent/WO2003039612A1/en active IP Right Grant
- 2002-11-08 AT AT05012112T patent/ATE461717T1/en not_active IP Right Cessation
- 2002-11-08 EP EP05012112A patent/EP1576970B1/en not_active Expired - Lifetime
- 2002-11-08 DE DE60221287T patent/DE60221287T4/en not_active Expired - Lifetime
- 2002-11-08 DK DK05012112.8T patent/DK1576970T3/en active
- 2002-11-08 EP EP10157210A patent/EP2201965A1/en not_active Withdrawn
-
2005
- 2005-05-31 US US11/140,811 patent/US20060008501A1/en not_active Abandoned
- 2005-08-24 JP JP2005242578A patent/JP2006051369A/en active Pending
-
2010
- 2010-04-26 US US12/767,289 patent/US20100209473A1/en not_active Abandoned
-
2013
- 2013-06-07 US US13/912,913 patent/US20130274319A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952419A (en) * | 1987-08-31 | 1990-08-28 | Eli Lilly And Company | Method of making antimicrobial coated implants |
WO2000062830A2 (en) * | 1999-04-19 | 2000-10-26 | Boston Scientific Limited | Coating medical devices using air suspension |
WO2002100455A2 (en) * | 2001-06-08 | 2002-12-19 | Baylor College Of Medicine | Use of ozone for the prevention of infection caused by medical devices |
EP1273314A1 (en) * | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
Cited By (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9050442B2 (en) | 1999-01-25 | 2015-06-09 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US7947015B2 (en) | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
EP2077127A2 (en) * | 2001-10-22 | 2009-07-08 | EV3 Peripheral, Inc. | Stent coatings containing HMG-CoA reductase inhibitors |
EP2077127A3 (en) * | 2001-10-22 | 2010-06-02 | EV3 Peripheral, Inc. | Stent coatings containing HMG-CoA reductase inhibitors |
US8961588B2 (en) | 2002-03-27 | 2015-02-24 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
US8871883B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible coating for implantable medical devices |
US8986726B2 (en) | 2002-12-11 | 2015-03-24 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8871236B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
JP4863489B2 (en) * | 2003-07-30 | 2012-01-25 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Bioabsorbable coating for implantable devices and method of making the same |
US8003123B2 (en) | 2003-07-30 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices and methods for fabricating the same |
JP2007500041A (en) * | 2003-07-30 | 2007-01-11 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Bioabsorbable coating for implantable devices and method of making the same |
WO2005016399A1 (en) * | 2003-08-11 | 2005-02-24 | Scimed Life Systems, Inc. | Medical devices containing antioxidant and therapeutic agent |
EP1663343A2 (en) * | 2003-09-15 | 2006-06-07 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
EP1663343A4 (en) * | 2003-09-15 | 2011-11-30 | Atrium Medical Corp | Application of a therapeutic substance to a tissue location using an expandable medical device |
US7572245B2 (en) | 2003-09-15 | 2009-08-11 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
JP2007509179A (en) * | 2003-10-21 | 2007-04-12 | メドロジックス・ディバイス・コーポレーション | Treatment of gamma-tocopherol for the prevention of restenosis |
US8101199B2 (en) | 2003-10-21 | 2012-01-24 | Celonova Biosciences, Inc. | Des-methyl-tocopherol therapy for restenosis prevention |
US8541014B2 (en) | 2003-10-21 | 2013-09-24 | Celonova Biosciences, Inc. | Gamma-tocopherol therapy for restenosis prevention |
WO2005053767A1 (en) * | 2003-11-11 | 2005-06-16 | K.U. Leuven Research & Development | Cis-hydrogenated fatty acid coating of medical devices |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US8652502B2 (en) | 2003-12-19 | 2014-02-18 | Cordis Corporation | Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury |
US9265597B2 (en) | 2003-12-19 | 2016-02-23 | Cordis Corporation; Wyeth LLC | Local vascular delivery of probucol in combination with sirolimus |
JP2005199058A (en) * | 2003-12-19 | 2005-07-28 | Cordis Corp | Local vascular delivery of trichostatin alone or by its combination with sirolimus for preventing restenosis after vascular defect |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US9265598B2 (en) | 2003-12-19 | 2016-02-23 | Cordis Corporation | Local vascular delivery of sirolimus to prevent restenosis following vascular injury |
AU2005216592B8 (en) * | 2004-02-28 | 2009-06-04 | Hemoteq Ag | Biocompatible coating, method, and use of medical surfaces |
EP1718347A2 (en) * | 2004-02-28 | 2006-11-08 | Hemoteq GmbH | Biocompatible coating, method, and use of medical surfaces |
WO2005082434A3 (en) * | 2004-02-28 | 2005-10-13 | Hemoteq Gmbh | Biocompatible coating, method, and use of medical surfaces |
JP2007523705A (en) * | 2004-02-28 | 2007-08-23 | ヘモテック アーゲー | Biocompatible coatings, methods, and uses on medical supplies surfaces |
EP1718347B1 (en) * | 2004-02-28 | 2017-03-08 | Hemoteq AG | Biocompatible coating, method, and use of medical surfaces |
EA012370B1 (en) * | 2004-02-28 | 2009-10-30 | Хемотек Аг | Stent with biocompatible coating and methods for producing thereof |
AU2005216592B2 (en) * | 2004-02-28 | 2009-05-07 | Hemoteq Ag | Biocompatible coating, method, and use of medical surfaces |
US9101697B2 (en) | 2004-04-30 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Hyaluronic acid based copolymers |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9375445B2 (en) | 2004-06-18 | 2016-06-28 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US8512734B2 (en) * | 2004-07-05 | 2013-08-20 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Biocompatible coating of medical devices |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
US8263102B2 (en) * | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US20090208552A1 (en) * | 2004-09-28 | 2009-08-20 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20150079191A1 (en) * | 2004-09-28 | 2015-03-19 | Atrium Medical Corporation | Cured gel and method of making |
US10016465B2 (en) | 2004-09-28 | 2018-07-10 | Atrium Medical Corporation | Cured gel and method of making |
EP1811933A2 (en) * | 2004-09-28 | 2007-08-01 | Atrium Medical Corporation | Barrier layer |
EP1804717A4 (en) * | 2004-09-28 | 2015-11-18 | Atrium Medical Corp | Drug delivery coating for use with a stent |
EP1811933A4 (en) * | 2004-09-28 | 2011-08-31 | Atrium Medical Corp | Barrier layer |
US9827352B2 (en) | 2004-09-28 | 2017-11-28 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US20090181937A1 (en) * | 2004-09-28 | 2009-07-16 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9682175B2 (en) | 2004-09-28 | 2017-06-20 | Atrium Medical Corporation | Coating material and medical device system including same |
US10869902B2 (en) | 2004-09-28 | 2020-12-22 | Atrium Medical Corporation | Cured gel and method of making |
US11793912B2 (en) | 2004-09-28 | 2023-10-24 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8795703B2 (en) * | 2004-09-28 | 2014-08-05 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US20060067975A1 (en) * | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | UV cured gel and method of making |
US8858978B2 (en) * | 2004-09-28 | 2014-10-14 | Atrium Medical Corporation | Heat cured gel and method of making |
US10792312B2 (en) | 2004-09-28 | 2020-10-06 | Atrium Medical Corporation | Barrier layer |
US9012506B2 (en) * | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8962023B2 (en) * | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
US9000040B2 (en) * | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US9339592B2 (en) | 2004-12-22 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
JP2006198408A (en) * | 2005-01-19 | 2006-08-03 | Heraeus Kulzer Gmbh | Antibiotic coating of transplant |
JP4575303B2 (en) * | 2005-01-19 | 2010-11-04 | ヘレーウス クルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング | Antibiotic coating of transplanted tissue |
CN100460022C (en) * | 2005-01-19 | 2009-02-11 | 贺利氏古萨有限公司 | Implant dedicated antibiotic coating |
EP1683531A1 (en) * | 2005-01-19 | 2006-07-26 | Heraeus Kulzer GmbH | Antibiotic coating of implants |
US8092824B2 (en) | 2005-01-19 | 2012-01-10 | Heraeus Kulzer Gmbh | Antibiotic coating of implants |
AU2005256092B2 (en) * | 2005-01-19 | 2008-01-10 | Heraeus Medical Gmbh | Antibiotic coating of implants |
US20100004738A1 (en) * | 2005-04-29 | 2010-01-07 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
US20100034867A1 (en) * | 2005-04-29 | 2010-02-11 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US11083823B2 (en) | 2005-09-28 | 2021-08-10 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US8124127B2 (en) * | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US9220820B2 (en) | 2005-10-15 | 2015-12-29 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US9339634B2 (en) | 2006-06-28 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Local delivery with a balloon covered by a cage |
US9216271B2 (en) | 2006-06-28 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Local delivery with a balloon covered by a cage |
US8388573B1 (en) | 2006-06-28 | 2013-03-05 | Abbott Cardiovascular Systems Inc. | Local delivery with a balloon covered by a cage |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
EP1880690A1 (en) * | 2006-07-17 | 2008-01-23 | Heraeus Kulzer GmbH | Dental implant system part with coating |
US7939146B2 (en) | 2006-08-07 | 2011-05-10 | Biotronik Vi Patent Ag | Marker composite for medical implants |
EP1886701A3 (en) * | 2006-08-07 | 2008-05-21 | BIOTRONIK VI Patent AG | Marker composite for medical implants |
EP1886701A2 (en) * | 2006-08-07 | 2008-02-13 | BIOTRONIK VI Patent AG | Marker composite for medical implants |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US8574627B2 (en) * | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
US9974931B2 (en) | 2007-08-03 | 2018-05-22 | Invatec Technology Center Gmbh | Pharmaceutical-coated medical products, the production thereof and the use thereof |
DE202008018649U1 (en) | 2007-08-03 | 2017-07-17 | Invatec Technology Center Gmbh | Improved drug-coated medical devices |
DE102007036685A1 (en) | 2007-08-03 | 2009-02-05 | Innora Gmbh | Improved drug-coated medical devices their manufacture and use |
EP3040089A1 (en) | 2007-08-03 | 2016-07-06 | Invatec Technology Center GMBH | Improved pharmaceutical-coated medical products and the production thereof |
EP2682138A3 (en) * | 2007-08-03 | 2014-08-13 | Invatec Technology Center GMBH | Improved pharmaceutical-coated medical products, the production thereof and the use thereof |
US9220875B2 (en) | 2007-08-03 | 2015-12-29 | Invatec Technology Center Gmbh | Pharmaceutical-coated medical products, the production thereof and the use thereof |
US8608689B2 (en) | 2007-08-03 | 2013-12-17 | Invatec Technology Center Gmbh | Pharmaceutical-coated medical products, the production thereof and the use thereof |
EP2682138A2 (en) | 2007-08-03 | 2014-01-08 | Invatec Technology Center GMBH | Improved pharmaceutical-coated medical products, the production thereof and the use thereof |
US10532189B2 (en) | 2007-08-29 | 2020-01-14 | Invatec Technology Center Gmbh | Controlled expansion balloon catheter |
US9216027B2 (en) | 2007-09-17 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Methods and devices for eluting agents to a vessel |
US8556849B2 (en) | 2007-09-17 | 2013-10-15 | Abbott Cardiovascular Systems Inc. | Methods and devices for eluting agents to a vessel |
US9636486B2 (en) | 2007-09-17 | 2017-05-02 | Abbott Cardiovascular Systems Inc. | Methods and devices for eluting agents to a vessel |
US8100855B2 (en) | 2007-09-17 | 2012-01-24 | Abbott Cardiovascular Systems, Inc. | Methods and devices for eluting agents to a vessel |
EP2191853A1 (en) * | 2007-09-28 | 2010-06-02 | Terumo Kabushiki Kaisha | In-vivo indwelling matter |
EP2191853A4 (en) * | 2007-09-28 | 2010-10-06 | Terumo Corp | In-vivo indwelling matter |
US8916188B2 (en) | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
EP2111880A2 (en) | 2008-04-24 | 2009-10-28 | BIOTRONIK VI Patent AG | Biodegradable metal stent |
DE102008020415A1 (en) | 2008-04-24 | 2009-10-29 | Biotronik Vi Patent Ag | Biodegradable metallic stents with wax layer |
US11166929B2 (en) | 2009-03-10 | 2021-11-09 | Atrium Medical Corporation | Fatty-acid based particles |
US10285964B2 (en) | 2009-03-10 | 2019-05-14 | Atrium Medical Corporation | Fatty-acid based particles |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US10864304B2 (en) | 2009-08-11 | 2020-12-15 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
EP2593141A4 (en) * | 2010-07-16 | 2016-02-17 | Atrium Medical Corp | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US11097035B2 (en) | 2010-07-16 | 2021-08-24 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
WO2013007653A1 (en) | 2011-07-08 | 2013-01-17 | Cardionovum Sp.Z.O.O. | Balloon catheter with a sirolimus coated catheter balloon for controlled release of sirolimus |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US10888617B2 (en) | 2012-06-13 | 2021-01-12 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
Also Published As
Publication number | Publication date |
---|---|
ATE367172T1 (en) | 2007-08-15 |
US20060008501A1 (en) | 2006-01-12 |
EP1463545B1 (en) | 2007-07-18 |
JP2006051369A (en) | 2006-02-23 |
US8460693B2 (en) | 2013-06-11 |
JP2005507754A (en) | 2005-03-24 |
EP1842567A3 (en) | 2008-01-02 |
DE60221287T2 (en) | 2008-04-03 |
EP1842567A2 (en) | 2007-10-10 |
US20100209473A1 (en) | 2010-08-19 |
US20130274319A1 (en) | 2013-10-17 |
EP2201965A1 (en) | 2010-06-30 |
US20050158361A1 (en) | 2005-07-21 |
EP1463545A1 (en) | 2004-10-06 |
EP1463545B3 (en) | 2008-12-10 |
DE60221287D1 (en) | 2007-08-30 |
ES2289153T7 (en) | 2009-06-18 |
DE60221287T4 (en) | 2009-06-25 |
ATE461717T1 (en) | 2010-04-15 |
ES2289153T3 (en) | 2008-02-01 |
EP1576970B1 (en) | 2010-03-24 |
CA2508907A1 (en) | 2003-05-15 |
CA2466432A1 (en) | 2003-05-15 |
DE60235775D1 (en) | 2010-05-06 |
EP1576970A1 (en) | 2005-09-21 |
DK1576970T3 (en) | 2010-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8460693B2 (en) | Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent | |
US8722077B2 (en) | Drug delivery coating for use with a stent | |
EP1663339B1 (en) | Endoluminal prosthesis comprising a therapeutic agent | |
US8962023B2 (en) | UV cured gel and method of making | |
US20060083768A1 (en) | Method of thickening a coating using a drug | |
WO2005053767A1 (en) | Cis-hydrogenated fatty acid coating of medical devices | |
US20090269330A1 (en) | Fatty acid triglycerides for making biocompatible coatings | |
US20100004738A1 (en) | Drug delivery coating for use with a medical device and methods of treating vascular injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2466432 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003541902 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002776619 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002776619 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10494892 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002776619 Country of ref document: EP |